Oncology Corporate Profile
AREVA Med is an AREVA subsidiary specializing in the development of innovative therapies to fight cancer. AREVA Med has developed new processes for producing high purity lead-212 ((2)(1)(2)Pb), a rare radioactive isotope that is currently at the heart of promising nuclear medicine research. In 2011, AREVA Med acquired Macrocyclics, the global leader in high performance chelating agent technology.
5/22/2015 09:02 pm